Avanos Medical (NYSE:AVNS) Stock Rating Lowered by StockNews.com

Avanos Medical (NYSE:AVNS) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Tuesday.

Avanos Medical Stock Performance

AVNS stock traded down $0.14 during trading on Tuesday, hitting $14.76. 460,320 shares of the company’s stock traded hands, compared to its average volume of 548,177. The company has a quick ratio of 1.46, a current ratio of 2.22 and a debt-to-equity ratio of 0.12. Avanos Medical has a 52 week low of $14.40 and a 52 week high of $25.36. The stock has a fifty day moving average price of $15.98 and a two-hundred day moving average price of $19.18. The stock has a market capitalization of $679.05 million, a price-to-earnings ratio of 43.41 and a beta of 1.17.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.03. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The company had revenue of $179.60 million during the quarter, compared to the consensus estimate of $177.23 million. As a group, equities analysts anticipate that Avanos Medical will post 1.32 EPS for the current fiscal year.

Insider Buying and Selling at Avanos Medical

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the completion of the sale, the senior vice president now directly owns 82,047 shares of the company’s stock, valued at approximately $1,251,216.75. This represents a 7.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Avanos Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Avanos Medical by 10.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 120,269 shares of the company’s stock valued at $1,915,000 after acquiring an additional 11,799 shares during the last quarter. Two Sigma Investments LP raised its holdings in Avanos Medical by 20.6% during the 4th quarter. Two Sigma Investments LP now owns 72,701 shares of the company’s stock worth $1,157,000 after buying an additional 12,422 shares during the period. State of Wyoming increased its holdings in shares of Avanos Medical by 132.0% in the 4th quarter. State of Wyoming now owns 5,137 shares of the company’s stock valued at $82,000 after purchasing an additional 2,923 shares during the period. ProShare Advisors LLC increased its holdings in shares of Avanos Medical by 44.4% in the 4th quarter. ProShare Advisors LLC now owns 13,693 shares of the company’s stock valued at $218,000 after purchasing an additional 4,210 shares during the period. Finally, Occudo Quantitative Strategies LP acquired a new position in shares of Avanos Medical in the 4th quarter valued at about $485,000. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.